Recruitment

Recruitment Status
Completed

Inclusion Criterias

Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
Age: 25-75 years
HbA1c 6,0-10 %
...
Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
Age: 25-75 years
HbA1c 6,0-10 %
BMI>25 kg/m2

Exclusion Criterias

Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
Pregnancy
Chronic alcohol abuse
...
Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
Pregnancy
Chronic alcohol abuse
Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)
Severe hepatic co-morbidity
Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin
Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.
Chronic or previous acute pancreatitis
Severe co-morbidity with limited life-expectancy
Severe asthma
Active cancer
Heart failure with a left ventricular ejection fraction </= 45%
Haemoglobin < 6.5 mmol/l
Atrial fibrillation
Inflammatory bowel disease.

Summary

Conditions
  • Microvascular Dysfunction
  • Type 2 Diabetes
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Single (Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 25 years and 75 years
Gender
Both males and females

Inclusion Criterias

Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
Age: 25-75 years
HbA1c 6,0-10 %
...
Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
Age: 25-75 years
HbA1c 6,0-10 %
BMI>25 kg/m2

Exclusion Criterias

Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
Pregnancy
Chronic alcohol abuse
...
Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
Pregnancy
Chronic alcohol abuse
Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)
Severe hepatic co-morbidity
Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin
Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.
Chronic or previous acute pancreatitis
Severe co-morbidity with limited life-expectancy
Severe asthma
Active cancer
Heart failure with a left ventricular ejection fraction </= 45%
Haemoglobin < 6.5 mmol/l
Atrial fibrillation
Inflammatory bowel disease.

Locations

Copenhagen, Capital region, 2400
Copenhagen, Capital region, 2400

Tracking Information

NCT #
NCT01931982
Collaborators
Not Provided
Investigators
  • Principal Investigator: Mette Zander, consultant Department of Endocrinology, Bispebjerg Hospital
  • Mette Zander, consultant Department of Endocrinology, Bispebjerg Hospital